Inhibiting EGFR signaling restores the expression of major histocompatibility complex (MHC) molecules, and enhances secretion of interferon-gamma (IFNγ) which increases PD-L1 expression on tumor and immune cells within the tumor microenvironment (TME) (25). Here, IFNG is linked to neoplasm.